CD274 and cutaneous melanoma: Immunotherapy has dramatically improved outcomes for patients with advanced cutaneous melanoma, but this clinical benefit has not been observed in metastatic uveal melanoma, probably due to a low mutational burden and low PD-L1 expression [116,117,118].